Adimmune Corporation
Adimmune Corporation, a leading biopharmaceutical company based in Taiwan (TW), has been at the forefront of vaccine development since its establishment in 1965. With a strong focus on the research, production, and distribution of vaccines, Adimmune has made significant strides in enhancing public health both locally and internationally. The company is renowned for its innovative vaccine solutions, including those for influenza and other infectious diseases, which are distinguished by their high efficacy and safety profiles. Adimmune's commitment to quality and research excellence has positioned it as a key player in the global vaccine market. Over the years, Adimmune has achieved numerous milestones, solidifying its reputation as a trusted provider of vaccines. Its strategic operations extend beyond Taiwan, reaching various regions, thereby contributing to global health initiatives and responding to emerging health challenges.
DitchCarbon Score
How does Adimmune Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adimmune Corporation's score of 28 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Adimmune Corporation's reported carbon emissions
In 2023, Adimmune Corporation reported total carbon emissions of approximately 16,778,000 kg CO2e, comprising 4,556,000 kg CO2e from Scope 1 and 12,223,000 kg CO2e from Scope 2 emissions. The company has shown a slight increase in emissions compared to 2022, where total emissions were about 16,775,000 kg CO2e, with Scope 1 at 4,572,000 kg CO2e and Scope 2 at 11,823,000 kg CO2e. Over the past few years, Adimmune's emissions have fluctuated, with Scope 1 emissions rising from 3,215,000 kg CO2e in 2020 to 4,556,000 kg CO2e in 2023, while Scope 2 emissions increased from 9,265,000 kg CO2e in 2020 to 12,223,000 kg CO2e in 2023. Notably, there have been no reported Scope 3 emissions during this period. Despite these figures, Adimmune Corporation has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or reduction strategies suggests that the company may be in the early stages of developing a comprehensive climate action plan. As the industry increasingly prioritises sustainability, it will be essential for Adimmune to establish clear commitments to reduce emissions and enhance their environmental performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 3,215,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,265,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Adimmune Corporation is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
